NCT03632915 (PADRE) is a clinical trial of Levetiracetam in Acute Kidney Injury, sponsored by University of Maryland, Baltimore.

Who is sponsoring NCT03632915?

NCT03632915 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT03632915?

Interventions in NCT03632915: Levetiracetam, Lacosamide, Phenytoin, Phenobarbital, Ketamine, Valproic Acid.

What condition does NCT03632915 study?

NCT03632915 studies Acute Kidney Injury, Renal Insufficiency, Renal Failure, Pharmacokinetics.

Is NCT03632915 still recruiting?

NCT03632915 is currently completed. Last updated 5 October 2021.

Last reviewed 2021-10-05 · How we verify

NCT03632915: PADRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetics of Antiepileptics in Patients on CRRT

Completed Last updated 5 October 2021

What this trial tests

trial testing Levetiracetam in Acute Kidney Injury in 18 participants. Completed in 31 December 2019.

Timeline

20 November 2017

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	University of Maryland, Baltimore
Status	Completed
Study type	OBSERVATIONAL
Enrollment	18
Start date	20 November 2017
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across United States

Drugs / interventions tested

Levetiracetam (levetiracetam) — full drug profile →
Lacosamide (lacosamide) — full drug profile →
Phenytoin
Phenobarbital
Ketamine (ketamine) — full drug profile →
Valproic Acid (valproic acid) — full drug profile →

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →
Renal Insufficiency — all drugs for Renal Insufficiency →
Renal Failure — all drugs for Renal Failure →
Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

University of Maryland, Baltimore

Who can join

Adults 18 to 80, any sex, with Acute Kidney Injury or Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to measure levels of any of the following AEDs (levetiracetam, phenobarbital, phenytoin, ketamine, valproic acid, lacosamide) in blood and effluent on critically ill patients receiving CRRT in order to characterize drug pharmacokinetics and optimize dosing strategies in patients on CRRT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01).
Kalaria SN, Armahizer M, McCarthy P, Badjatia N, et al · · 2020 · cited 12× · PMID 32223067 · DOI 10.1111/cts.12782

Verify or expand the search:

Other trials of Levetiracetam

Trials testing the same drug.

NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
NCT07072624 — Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial) · Phase 4 · recruiting
NCT07046611 — Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children · Phase 2, PHASE3 · recruiting
NCT06773364 — Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial · Phase 3 · recruiting
NCT07052136 — Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus · NA · completed

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03632915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 5 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing